GLX Analytix is an award-winning Silicon Valley venture- and strategic-backed personalized medicine company, pioneering a groundbreaking diagnostics and monitoring platform. Its proprietary GLX Signature Platform is powered by novel vascular biology and AI technology, designed to transform the care of patients with neurodegenerative, autoimmune, cardiovascular, and psychiatric diseases. Leveraging advanced glycobiology research and a new class of blood biomarkers, GLX Analytix also delivers innovative solutions for therapeutic strategies.
With partnerships at leading medical institutions in the United States and Europe, the company aims to accelerate noninvasive, cost-effective, and highly accessible personalized care for patients worldwide. Recognized by industry leaders, GLX Analytix is poised to revolutionize early detection and treatment monitoring in conditions such as Alzheimer’s Disease, Multiple Sclerosis, ALS, and Major Depressive Disorder.
Company Details
- Employees
- 14
- Address
- Copenhagen, Captial Region 2100, Dk
- Industry
- Biotechnology Research
- NAICS
-
Research and Development in Biotechnology (except Nanobiotechnology)
- Website
- glxanalytix.com
- Keywords
- New York.
- HQ
- Copenhagen, Captial Region
Glx Analytix Questions
Glx Analytix's website is glxanalytix.com
Glx Analytix's LinkedIn profile is https://dk.linkedin.com/company/glx
Glx Analytix has
14 employees.
View email and phone details for 14
employees at Glx Analytix.
Glx Analytix's industry is
Biotechnology Research
Glx Analytix's top competitors are
Eifo,
Digitaldx Ventures,
Loma Therapeutics,
Tgen - Part Of City Of Hope,
Moleculera Biosciences,
Cirqle Biomedical,
Alzheimer's Drug Discovery Foundation,
Oxford Nanopore Technologies,
Cleveland Diagnostics,
Vesper Bio.
Glx Analytix's categories are Biotechnology Research
